Literature DB >> 27884934

Chronic neuropathic pain severity is determined by lesion level in aquaporin 4-antibody-positive myelitis.

George Tackley1, Domizia Vecchio1,2, Shahd Hamid3, Maciej Jurynczyk1, Yazhuo Kong1, Rosie Gore1, Kerry Mutch3, Mark Woodhall1, Patrick Waters1, Angela Vincent1, Maria Isabel Leite1, Irene Tracey1, Anu Jacob3, Jacqueline Palace1.   

Abstract

IMPORTANCE: Chronic, intractable neuropathic pain is a common and debilitating consequence of neuromyelitis optica spectrum disorder (NMOSD) myelitis, with no satisfactory treatment; few studies have yet to explore its aetiology.
OBJECTIVE: To establish if myelitis-associated chronic pain in NMOSD is related to the craniocaudal location of spinal cord lesions.
METHOD: (1) Retrospective cohort of 76 aquaporin 4-antibody (AQP4-Ab)-positive patients from Oxford and Liverpool's national NMOSD clinics, assessing current pain and craniocaudal location of cord lesion contemporary to pain onset. (2) Focused prospective study of 26 AQP4-Ab-positive Oxford patients, a subset of the retrospective cohort, assessing current craniocaudal lesion location and current pain.
RESULTS: Patients with isolated thoracic cord myelitis at the time of pain onset were significantly more disabled and suffered more pain. Cervical and thoracic lesions that persisted from pain onset to 'out of relapse' follow-up (current MRI) had highly significant (p<0.01) opposing effects on pain scores (std. β=-0.46 and 0.48, respectively). Lesion length, total lesion burden and number of transverse myelitis relapses did not correlate with pain.
CONCLUSIONS: Persistent, caudally located (ie, thoracic) cord lesions in AQP4-Ab-positive patients associate with high postmyelitis chronic pain scores, irrespective of number of myelitis relapses, lesion length and lesion burden. Although disability correlated with pain in isolation, it became an insignificant predictor of pain when analysed alongside craniocaudal location of lesions. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27884934     DOI: 10.1136/jnnp-2016-314991

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  8 in total

Review 1.  Astrocytes in chronic pain and itch.

Authors:  Ru-Rong Ji; Christopher R Donnelly; Maiken Nedergaard
Journal:  Nat Rev Neurosci       Date:  2019-09-19       Impact factor: 34.870

2.  Association Between Magnetic Resonance Imaging-Based Spinal Morphometry and Sensorimotor Behavior in a Hemicontusion Model of Incomplete Cervical Spinal Cord Injury in Rats.

Authors:  Jyothsna Chitturi; Basavaraju G Sanganahalli; Peter Herman; Fahmeed Hyder; Li Ni; Stella Elkabes; Robert Heary; Sridhar S Kannurpatti
Journal:  Brain Connect       Date:  2020-10-29

3.  Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders.

Authors:  Susanna Asseyer; Felix Schmidt; Claudia Chien; Michael Scheel; Klemens Ruprecht; Judith Bellmann-Strobl; Alexander U Brandt; Friedemann Paul
Journal:  Mult Scler J Exp Transl Clin       Date:  2018-08-30

4.  Co-administration of human adipose-derived stem cells and low-level laser to alleviate neuropathic pain after experimental spinal cord injury.

Authors:  Arash Sarveazad; Atousa Janzadeh; Gholamreza Taheripak; Sima Dameni; Mahmoud Yousefifard; Farinaz Nasirinezhad
Journal:  Stem Cell Res Ther       Date:  2019-06-24       Impact factor: 6.832

5.  Difference in fatigue and pain between neuromyelitis optica spectrum disorder and multiple sclerosis.

Authors:  Hiroki Masuda; Masahiro Mori; Akiyuki Uzawa; Tomohiko Uchida; Ryohei Ohtani; Satoshi Kuwabara
Journal:  PLoS One       Date:  2020-04-06       Impact factor: 3.240

Review 6.  Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders.

Authors:  Andrea Salazar-Camelo; Naveen George; Hesham Abboud; Sarah M Planchon; Marcelo Matiello; Maureen A Mealy; Andrew Goodman
Journal:  J Neurol       Date:  2021-09-05       Impact factor: 4.849

7.  The risk factors of neuropathic pain in neuromyelitis optica spectrum disorder: a retrospective case-cohort study.

Authors:  Xiaojun Li; Haoyou Xu; Min Zhao; Yuanqi Zhao; Zequan Zheng; Huiying Ouyang; Guixian Chen; Zhenzhen Lou; Haoxuan Chen; Jiahui Zhang; Yibo Zhan; Hui Mao; Changlin Zhang
Journal:  BMC Neurol       Date:  2022-08-19       Impact factor: 2.903

8.  Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder: A Cross-Sectional Study of 166 AQP4 Antibody-Seropositive Patients.

Authors:  Ilya Ayzenberg; Daniel Richter; Eugenia Henke; Susanna Asseyer; Friedemann Paul; Corinna Trebst; Martin W Hümmert; Joachim Havla; Tania Kümpfel; Marius Ringelstein; Orhan Aktas; Brigitte Wildemann; Sven Jarius; Vivien Häußler; Jan-Patrick Stellmann; Makbule Senel; Luisa Klotz; Hannah L Pellkofer; Martin S Weber; Marc Pawlitzki; Paulus S Rommer; Achim Berthele; Klaus-Dieter Wernecke; Kerstin Hellwig; Ralf Gold; Ingo Kleiter
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-04-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.